MenSCs, on the other hand, target the AMPK-mTOR signaling pathway by secreting the novel regulatory factor Rnf186, which improves lipid metabolism and insulin resistance in MASLD mice, thereby alleviating the symptoms of MASLD (63). Here, MTOR is linked to metabolic dysfunction-associated steatotic liver disease.